Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls

Sheida Yahyazadeh , Nafiseh Esmaeil , Vahid Shaygannejad, Omid Mirmosayyeb

Abstract


Background and purpose: The use of anti-CD20 monoclonal antibodies like rituximab (RTX) to deplete B cells has practical therapeutic implications in multiple sclerosis (MS) patients. However, the therapy's impact on other immune cells is also important. Therefore, in this study, we assessed the effects of RTX therapy on Tfh cells, T cells, T cells priming, and monocytes in MS patients compared to newly-diagnosed MS patients and healthy subjects.

Experimental approach: Thirty newly-diagnosed and RTX-treated MS patients and healthy control were included. Peripheral blood mononuclear cells were isolated from whole blood for assessment of Tfh cells, CD4+, CD8+, CD4+CD45RA+, CD3+HLA-DR+, and CD3+CD4+CD25+ T cells by flow cytometry. Whole blood was lysed by lysis solution to assess CD45+CD14+ monocytes by flow cytometry. Also, the serum level of interleukin 21 was measured by the ELISA method.

Findings / Results: We showed that RTX treatment led to a decrease in Tfh cells and their predominant cytokine, interleukin 21. Also, we found a statistically significant reduction in CD3+HLA-DR+ and CD3+CD4+CD25+ T cells in RTX-treated patients compared to new cases and healthy control. Moreover, we found a decrease in the CD45+ CD14+ monocyte population in the RTX-treated group compared to the healthy control.

Conclusion and implications: Our data suggest that following treatment with RTX, Tfh cells, monocytes, and T cells priming declined happened, and fewer T cells were activated. Also, due to the interaction between B cells and Tfh cells, Tfh targeting could be assessed as a therapeutic strategy in MS.


Keywords


Follicular; Multiple sclerosis; Rituximab; T cells priming; T helper cells.

Full Text:

PDF

References


Reali C, Magliozzi R, Roncaroli F, Nicholas R, Howell OW, Reynolds R. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol. 2020;30(4);779-793.

DOI: 10.1111/bpa.12841.

Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Perspec Med. 2018;8(4):a029025,1-15.

DOI: 10.1101/cshperspect.a029025.

Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149-159.

DOI: 10.1038/nri3802.

Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW. Altered B cell signalling in autoimmunity. Nat Rev Immunol. 2017;17(7):421-436.

DOI: 10.1038/nri.2017.24.

Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol. 2012;12(2):136-148.

DOI: 10.1038/nri3152.

Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2020;26(2):137-152.

DOI: 10.1177/1352458519858604.

Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clinic Prac Neurol. 2008;4(10):557-567.

DOI: 10.1038/ncpneuro0901.

Arababadi MK, Mosavi R, Khorramdelazad H, Yaghini N, Rezazadeh Zarandi E, Araste M, et al. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVexTM in relapsing-remitting multiple sclerosis in Iranian patients. Biomark Med. 2010;4(5):755-759.

DOI: 10.2217/bmm.10.81

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089-1104.

DOI: 10.1093/brain/awm038.

Emami J, Ansarypour Z. Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis. Res Pharm Sci. 2019;14(6):471–487.

DOI: 10.4103/1735-5362.272534.

King C. A fine romance: T follicular helper cells and B cells. Immunity. 2011;34(6):827-829.

DOI: 10.1016/j.immuni.2011.06.007.

Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity. 2008;29(1):127-137.

DOI: 10.1016/j.immuni.2008.06.001.

Huber JE, Chang Y, Meinl I, Kümpfel T, Meinl E, Baumjohann D. Fingolimod profoundly reduces frequencies and alters subset composition of circulating T follicular helper cells in multiple sclerosis patients. J Immunol. 2020;204(5): 1101-1110.

DOI: 10.4049/jimmunol.1900955.

Quinn JL, Axtell RC. Emerging role of follicular t helper cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Intj Mol Sci. 2018;19(10):3233-3249.

DOI: 10.3390/ijms19103233.

Fan X, Lin C, Han J, Jiang X, Zhu J, Jin T. Follicular helper CD4+ T cells in human neuroautoimmune diseases and their animal models. Mediators Inflamm. 2015;2015;1-12.

DOI: 10.1155/2015/638968.

Kurata I, Matsumoto I, Sumida T. T follicular helper cell subsets: a potential key player in autoimmunity. Immunol Med. 2020;44(1):1-9.

DOI: 10.1080/25785826.2020.1776079.

Mintz MA, Cyster JG. T follicular helper cells in germinal center B cell selection and lymphomagenesis. Immunol Rev. 2020; 296(1):48-61.

DOI: 10.1111/imr.12860.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.

DOI: 10.1002/ana.22366.

Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol. 2019;266(1):57-67.

DOI: 10.1007/s00415-018-9092-4.

Zhao C, Li HZ, Zhao DD, Ma C, Wu F, Bai YN, et al. Increased circulating T follicular helper cells are inhibited by rituximab in neuromyelitis optica spectrum disorder. Front Neurol. 2017;8:104-112.

DOI: 10.3389/fneur.2017.00104.

Quinn JL, Kumar G, Agasing A, Ko RM, Axtell RC. Role of TFH cells in promoting T helper 17-induced neuroinflammation. Front Immunol. 2018;9:382-393.

DOI: 10.3389/fimmu.2018.00382.

Xu X, Shi Y, Cai Y, Zhang Q, Yang F, Chen H, et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS One. 2013;8(11):e79858,1-8.

DOI: 10.1371/journal.pone.0079858.

Aloulou M, Carr EJ, Gador M, Bignon A, Liblau RS, Fazilleau N, et al. Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat Commun. 2016;7:10579-10588.

DOI: 10.1038/ncomms10579.

Sage PT, Sharpe AH. T follicular regulatory cells. Immunol Rev. 2016;271(1):246-259.

DOI: 10.1111/imr.12411.

Suarez A, Mozo L, Gutierrez C. Generation of CD4(+)CD45RA(+) effector T cells by stimulation in the presence of cyclic adenosine 5'-monophosphate-elevating agents. J Immunol. 2002;169(3):1159-1167.

DOI: 10.4049/jimmunol.169.3.1159.

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166,1-10.

DOI: 10.1126/scitranslmed.aab4176.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.